China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced a clinical development collaboration with US-based ArriVent Biopharma Inc. The partnership aims to evaluate the combination of InnoCare’s novel SHP2 allosteric inhibitor, ICP-189, with ArriVent’s furmonertinib, a highly brain-penetrant and broadly active mutation-selective EGFR inhibitor.
Combining ICP-189 and Furmonertinib for Solid Tumor Treatments
ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, developed by InnoCare for the treatment of solid tumors. It can be used as a single agent and/or in combination with other antitumor agents. In a dose escalation study, ICP-189 demonstrated favorable pharmacokinetics, a long half-life, and a favorable safety and tolerability profile.
Furmonertinib’s Background and Global Studies
Furmonertinib was originally discovered by Shanghai-based Allist Pharmaceuticals Inc., (688578.SH) and licensed to ArriVent for ex-China development in a July 2021 deal valued at up to USD 800 million. ArriVent is conducting global studies for the molecule as a treatment for advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR or HER2 mutations, including exon 20 insertion mutations. Allist secured a first approval for furmonertinib in China in March 2021 as a first-line treatment for locally advanced or metastatic NSCLC with EGFR exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations.-Fineline Info & Tech
